{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:04:32Z","timestamp":1787918672730,"version":"build-2784847793"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010523","name":"Centre for Addiction and Mental Health in Toronto, Ontario, Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto in Ontario, Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.pnpbp.2020.110065","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T21:37:42Z","timestamp":1597959462000},"page":"110065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Opioid-sparing effects of cannabinoids: Myth or reality?"],"prefix":"10.1016","volume":"106","author":[{"given":"Bernard","family":"Le Foll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2020.110065_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.2011.188","article-title":"Cannabinoid-opioid interaction in chronic pain","volume":"90","author":"Abrams","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejim.2018.01.019","article-title":"Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly","volume":"49","author":"Abuhasira","year":"2018","journal-title":"Eur. J. Intern. Med."},{"issue":"11","key":"10.1016\/j.pnpbp.2020.110065_bb0015","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00213-019-05293-1","article-title":"Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans","volume":"236","author":"Babalonis","year":"2019","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110065_bb0020","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jamainternmed.2014.4005","article-title":"Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010","volume":"174","author":"Bachhuber","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"8","key":"10.1016\/j.pnpbp.2020.110065_bb0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/BF03022793","article-title":"Effects of nabilone, a synthetic cannabinoid, on postoperative pain","volume":"53","author":"Beaulieu","year":"2006","journal-title":"Can. J. Anaesth."},{"issue":"10028","key":"10.1016\/j.pnpbp.2020.110065_bb0030","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(16)00161-6","article-title":"Use of and barriers to access to opioid analgesics: a worldwide, regional, and national study","volume":"387","author":"Berterame","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0035","first-page":"17","article-title":"Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain","author":"Boehnke","year":"2016","journal-title":"J. Pain"},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110065_bb0040","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jpain.2019.01.010","article-title":"Pills to pot: observational analyses of Cannabis substitution among medical Cannabis users with chronic pain","volume":"20","author":"Boehnke","year":"2019","journal-title":"J. Pain"},{"issue":"5","key":"10.1016\/j.pnpbp.2020.110065_bb0045","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/jamainternmed.2018.0266","article-title":"Association between US state medical Cannabis Laws and Opioid prescribing in the Medicare part D population","volume":"178","author":"Bradford","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"5","key":"10.1016\/j.pnpbp.2020.110065_bb0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/09540261.2018.1509842","article-title":"What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review","volume":"30","author":"Campbell","year":"2018","journal-title":"Int. Rev. Psychiatr."},{"issue":"7","key":"10.1016\/j.pnpbp.2020.110065_bb0055","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2468-2667(18)30110-5","article-title":"Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study","volume":"3","author":"Campbell","year":"2018","journal-title":"Lancet Public Health"},{"issue":"49","key":"10.1016\/j.pnpbp.2020.110065_bb0060","doi-asserted-by":"crossref","first-page":"15078","DOI":"10.1073\/pnas.1518393112","article-title":"Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century","volume":"112","author":"Case","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008688","article-title":"Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors","volume":"5","author":"Cencioni","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0070","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.drugalcdep.2017.10.021","article-title":"Medical marijuana laws and adolescent use of marijuana and other substances: alcohol, cigarettes, prescription drugs, and other illicit drugs","volume":"183","author":"Cerda","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2003.09.038","article-title":"Synergistic interactions between cannabinoid and opioid analgesics","volume":"74","author":"Cichewicz","year":"2004","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110065_bb0080","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1124\/jpet.102.046870","article-title":"Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol","volume":"305","author":"Cichewicz","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(24)38212-6","article-title":"Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification","volume":"289","author":"Cichewicz","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2005.09.039","article-title":"Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol","volume":"525","author":"Cichewicz","year":"2005","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110065_bb0095","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41386-018-0011-2","article-title":"Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability","volume":"43","author":"Cooper","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0100","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2147\/JPR.S134330","article-title":"Cannabis as a substitute for prescription drugs - a cross-sectional study","volume":"10","author":"Corroon","year":"2017","journal-title":"J. Pain Res."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2007.04.010","article-title":"Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat","volume":"567","author":"Cox","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/bjp.2008.175","article-title":"The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors","volume":"154","author":"da Fonseca Pacheco","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2014.11.031","article-title":"Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the pain and opioids IN treatment (POINT) study","volume":"147","author":"Degenhardt","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/j.0953-816X.2004.03177.x","article-title":"Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain","volume":"19","author":"Finn","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110065_bb0125","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1152\/physrev.00004.2003","article-title":"Role of endogenous cannabinoids in synaptic signaling","volume":"83","author":"Freund","year":"2003","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuropharm.2016.12.008","article-title":"Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists","volume":"116","author":"Grenald","year":"2017","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110065_bb0135","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.17269\/CJPH.108.6130","article-title":"Therapeutic use of cannabis: prevalence and characteristics among adults in Ontario, Canada","volume":"108","author":"Hamilton","year":"2017","journal-title":"Can. J. Public Health"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0140","doi-asserted-by":"crossref","DOI":"10.1097\/AJP.0000000000000364","article-title":"The effect of medicinal cannabis on pain and quality of life outcomes in chronic pain: a prospective open-label study","volume":"32","author":"Haroutounian","year":"2016","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0145","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"J. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/S0006-8993(98)01321-3","article-title":"Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord","volume":"822","author":"Hohmann","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0155","article-title":"Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide","volume":"857","author":"Houser","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0160","doi-asserted-by":"crossref","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"issue":"11","key":"10.1016\/j.pnpbp.2020.110065_bb0165","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of Cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.pain.2005.12.018","article-title":"CB2 cannabinoid receptor mediation of antinociception","volume":"122","author":"Ibrahim","year":"2006","journal-title":"Pain"},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110065_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222577","article-title":"Substitution of marijuana for opioids in a national survey of US adults","volume":"14","author":"Ishida","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pnpbp.2020.110065_bb0446","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","article-title":"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain","volume":"39","author":"Johnson","year":"2010","journal-title":"Journal of pain and symptom management"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0180","first-page":"17","article-title":"Involvement of peripheral cannabinoid and opioid receptors in beta-caryophyllene-induced antinociception","author":"Katsuyama","year":"2013","journal-title":"Eur J Pain"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0185","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.drugalcdep.2015.05.014","article-title":"Is cannabis use associated with less opioid use among people who inject drugs?","volume":"153","author":"Kral","year":"2015","journal-title":"Drug Alcohol Depend."},{"issue":"11","key":"10.1016\/j.pnpbp.2020.110065_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002967","article-title":"Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: a longitudinal analysis","volume":"16","author":"Lake","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0195","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-008-1157-0","article-title":"Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception","volume":"199","author":"Li","year":"2008","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.pnpbp.2020.110065_bb0200","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1111\/add.14382","article-title":"Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014","volume":"113","author":"Liang","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0205","article-title":"Morphine, melatonin, marijuana, Magnolia and MYRRH as the \u201cfive m\u201d schedule in the treatment of cancer pain and the possible dose-dependency of the antitumor and analgesic effects of the pineal hormone melatonin","volume":"34","author":"Lissoni","year":"2014","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.pnpbp.2020.110065_bb0210","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2105\/AJPH.2017.304059","article-title":"Recreational Cannabis legalization and opioid-related deaths in Colorado, 2000-2015","volume":"107","author":"Livingston","year":"2017","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0215","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drugpo.2017.01.011","article-title":"Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients","volume":"42","author":"Lucas","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0220","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.113.204099","volume":"345","author":"Maguire","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.pnpbp.2020.110065_bb0225","first-page":"119","article-title":"Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring","volume":"6","author":"Maida","year":"2008","journal-title":"J. Support Oncol."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/S0165-6147(99)01339-5","article-title":"Pharmacological and biochemical interactions between opioids and cannabinoids","volume":"20","author":"Manzanares","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0235","first-page":"378","article-title":"Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception","author":"Mason","year":"1999","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2020.110065_bb0240","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/QAI.0000000000001998","article-title":"Marijuana use is not associated with changes in opioid prescriptions or pain severity among people living with HIV and chronic pain","volume":"81","author":"Merlin","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"2","key":"10.1016\/j.pnpbp.2020.110065_bb0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/QAI.0000000000002119","article-title":"Marijuana use and its associations with pain, opioid dose, and HIV viral suppression among persons living with HIV on chronic opioid therapy","volume":"82","author":"Merlin","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/S0304-3959(03)00163-5","article-title":"The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions","volume":"105","author":"Naef","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2007.10.018","article-title":"Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy","volume":"9","author":"Narang","year":"2008","journal-title":"J. Pain"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0260","series-title":"The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research","author":"National Academies of Sciences & Medicine","year":"2017"},{"issue":"9","key":"10.1016\/j.pnpbp.2020.110065_bb0265","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/npp.2017.51","article-title":"Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis","volume":"42","author":"Nielsen","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0270","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.drugalcdep.2015.11.039","article-title":"Nonmedical prescription pain reliever and alcohol consumption among cannabis users","volume":"159","author":"Novak","year":"2016","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110065_bb0275","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1176\/appi.ajp.2017.17040413","article-title":"Cannabis use and risk of prescription opioid use disorder in the United States","volume":"175","author":"Olfson","year":"2018","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110065_bb0280","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/add.13741","article-title":"Do more robust prescription drug monitoring programs reduce prescription opioid overdose?","volume":"112","author":"Pardo","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0285","doi-asserted-by":"crossref","DOI":"10.1038\/sj.ijo.0803272","article-title":"The pharmacology of cannabinoid receptors and their ligands: an overview","volume":"30","author":"Pertwee","year":"2006","journal-title":"Int. J. Obes."},{"issue":"4","key":"10.1016\/j.pnpbp.2020.110065_bb0290","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5055\/jom.2017.0391","article-title":"Implications of prescription drug monitoring and medical cannabis legislation on opioid overdose mortality","volume":"13","author":"Phillips","year":"2017","journal-title":"J. Opioid Manag."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2012.01.003","article-title":"Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial","volume":"13","author":"Portenoy","year":"2012","journal-title":"J. Pain"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0300","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jhealeco.2017.12.007","article-title":"Do medical marijuana laws reduce addictions and deaths related to pain killers?","volume":"58","author":"Powell","year":"2018","journal-title":"J. Health Econ."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)21168-5","article-title":"The role of endogenous opioids in enhancing the antinociception produced by the combination of DELTA9-tetrahydrocannabinol and morphine in the spinal cord","volume":"279","author":"Pugh","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(24)36640-6","article-title":"Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord","volume":"281","author":"Pugh","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/S0014-2999(96)00752-2","article-title":"Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors","volume":"318","author":"Reche","year":"1996","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2020.110065_bb0447","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/can.2017.0012","article-title":"Cannabis as a substitute for opioid-based pain medication: patient self-report","volume":"2","author":"Reiman","year":"2017","journal-title":"Cannabis and cannabinoid research"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0320","article-title":"Pain and the global burden of disease","volume":"157","author":"Rice","year":"2015","journal-title":"Pain"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2005.11.036","article-title":"Synergistic affective analgesic interaction between delta-9- tetrahydrocannabinol and morphine","volume":"530","author":"Roberts","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0330","doi-asserted-by":"crossref","DOI":"10.1097\/00001756-200112040-00017","article-title":"CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn","volume":"12","author":"Salio","year":"2001","journal-title":"NeuroReport"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0335","article-title":"DELTA9-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperativepain","volume":"55","author":"Seeling","year":"2006","journal-title":"Anaesthesist"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0340","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsat.2017.03.012","article-title":"Medical cannabis use among patients with chronic pain in an interdisciplinary pain rehabilitation program: characterization and treatment outcomes","volume":"77","author":"Shah","year":"2017","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0345","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.drugalcdep.2017.01.006","article-title":"Medical marijuana policies and hospitalizations related to marijuana and opioid pain reliever","volume":"173","author":"Shi","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"26","key":"10.1016\/j.pnpbp.2020.110065_bb0350","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1073\/pnas.1903434116","article-title":"Association between medical cannabis laws and opioid overdose mortality has reversed over time","volume":"116","author":"Shover","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)38633-7","article-title":"Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice","volume":"268","author":"Smith","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/S0091-3057(98)00012-4","article-title":"The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol","volume":"60","author":"Smith","year":"1998","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2007.06.001","article-title":"Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors","volume":"571","author":"Smith","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2020.110065_bb0370","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1080\/10826084.2017.1416408","article-title":"Cannabis use is associated with lower odds of prescription opioid analgesic use among HIV-infected individuals with chronic pain","volume":"53","author":"Sohler","year":"2018","journal-title":"Subst Use Misuse"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0375","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjp.0706045","article-title":"Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice","volume":"144","author":"Tham","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0380","doi-asserted-by":"crossref","DOI":"10.1046\/j.0953-816x.2001.01558.x","article-title":"Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewardingeffect","volume":"13","author":"Valverde","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2005.01.021","article-title":"Molecular and cellular basis of cannabinoid and opioid interactions","volume":"81","author":"Vigano","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"11","key":"10.1016\/j.pnpbp.2020.110065_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187795","article-title":"Associations between medical cannabis and prescription opioid use in chronic pain patients: a preliminary cohort study","volume":"12","author":"Vigil","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0395","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain \u2014 misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0400","doi-asserted-by":"crossref","DOI":"10.1097\/FBP.0b013e328348ed22","article-title":"THC-methadone and THC-naltrexone interactions on discrimination, antinociception, and locomotion in rats","volume":"22","author":"Wakley","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(25)10720-9","article-title":"Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice","volume":"262","author":"Welch","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.pnpbp.2020.110065_bb0410","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/jamainternmed.2018.1007","article-title":"Association of medical and adult-use marijuana laws with opioid prescribing for medicaid enrollees","volume":"178","author":"Wen","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2006.04.003","article-title":"Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by \u03b49-tetrahydrocannabinol","volume":"539","author":"Williams","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0420","doi-asserted-by":"crossref","unstructured":"Williams, J., Haller, V.L., Stevens, D.L., Welch, S.P., 2008. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. Eur. J. Pharmacol. 584.","DOI":"10.1016\/j.ejphar.2007.12.035"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0425","first-page":"55","article-title":"Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception","author":"Wilson","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0430","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-46450-2_7","article-title":"The role of the endocannabinoid system in pain","volume":"227","author":"Woodhams","year":"2015","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110065_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/S0304-3959(03)00245-8","article-title":"Topical cannabinoid enhances topical morphine antinociception","volume":"105","author":"Yesilyurt","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0440","doi-asserted-by":"crossref","DOI":"10.1177\/1744806917728227","article-title":"Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain","volume":"13","author":"Yuill","year":"2017","journal-title":"Mol. Pain"},{"key":"10.1016\/j.pnpbp.2020.110065_bb0445","first-page":"15","article-title":"Risk factors for serious prescription opioid-related toxicity or overdose among veterans health administration patients","author":"Zedler","year":"2014","journal-title":"Pain Med."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858462030381X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858462030381X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:51:22Z","timestamp":1759521082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858462030381X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":91,"alternative-id":["S027858462030381X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110065","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid-sparing effects of cannabinoids: Myth or reality?","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110065"}}